Logo: http://www.protalix.com/index.asp, Non-free logo, via Wikipedia6
Israeli pharmaceutical company
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.3 It was founded by Joseph Chaaltiel.1 It is headquartered in Karmiel.1 Its shares trade on NYSE under the symbol PLX.1Wikipedia text CC BY-SA 4.0
$2.71up 0.10 (4.02%)Price as of Oct 15, 2026 at 17:33 UTC
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Cost of revenueResearch and developmentSelling, general and admin
Cost of revenue46¢$27.0M
Research and development33¢$19.6M
Selling, general and admin20¢$11.7M
Income tax2¢$996.0K
Out of $52.7M in revenue.9 The company lost money this year.
Financial statements
Revenue101112139$52.7M in 2025−4% since 2019Operating income101112139-$5.5M in 2025−49% since 2019Net income101112139-$6.6M in 2025−64% since 2019
Revenue1415$19.9M in Q2 FY2026−41% since Q1 FY2026Operating income1415$4.7M in Q2 FY2026−78% since Q1 FY2026Net income1415$3.8M in Q2 FY2026−79% since Q1 FY2026
Total assets16101112139$82.3M in 2025+81% since 2019Total liabilities16101112139$34.1M in 2025−71% since 2019Shareholders’ equity1112139$48.2M in 2025Cash16101112139$14.7M in 2025−17% since 2019
Total assets1415$110.3M in Q2 FY2026+34% since Q1 FY2025Total liabilities1415$38.9M in Q2 FY2026+14% since Q1 FY2025Shareholders’ equity1415$71.4M in Q2 FY2026+48% since Q1 FY2025Cash1415$27.4M in Q2 FY2026+87% since Q1 FY2025
Cash from operations101112139-$12.0M in 2025−38% since 2019Capital spending101112139$1.6M in 2025+161% since 2019Free cash flow101112139-$13.6M in 2025−32% since 2019
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Protalix Biotherapeutics Inc sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Protalix Biotherapeutics Inc
Alapkezelo Zrt. Hold Filed SCHEDULE 13G on Protalix Biotherapeutics Inc, latest Oct 15, 2026
MAK Capital Fund LP Filed SCHEDULE 13G/A on Protalix Biotherapeutics Inc, latest Mar 30, 2026 (2 filings since Mar 4, 2026)
WHITEBOX ADVISORS LLC Filed SC 13G/A on Protalix Biotherapeutics Inc, latest Oct 25, 2024 (2 filings since Jun 9, 2022)
Marius Nacht Filed SC 13G/A on Protalix Biotherapeutics Inc, latest Jan 2, 2024 (3 filings since Jan 31, 2022)
HIGHBRIDGE CAPITAL MANAGEMENT LLC Filed SC 13G/A on Protalix Biotherapeutics Inc, latest Feb 14, 2022 (2 filings since Feb 11, 2022)
Protalix Biotherapeutics IncKarmiel, Israel
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Protalix Biotherapeutics Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Our headquarters, including a manufacturing facility, executive offices and other facilities, are located in Carmiel, Israel. We also maintain a U.S. corporate office in Hackensack, New Jersey. Our facilities in Israel currently contain approximately 1,466 sq/m of manufacturing space and 316 sq/m for a pilot plant, 1,057 sq/m for offsite warehouse space and approximately 4,400 sq/m of laboratories, front warehouse and office space, and are leased at a rate of approximately $90,000 per month. In addition, we are entitled to use an additional 1,347 sq/m in the same facility, which we may utilize in connection with any future expansion of our manufacturing facilities. Our facilities are equipped with the requisite laboratory services required to conduct our business, and we believe that the existing facilities are adequate to meet our needs for the foreseeable future. Our original lease for the facility was in effect until 2016 and included three options to extend the leases for additional five-year periods. The leases have been amended to provide that the third option period for all leases will end on December 31, 2031, and will be associated with a uniform rent increase equal to 7.5%. Thereafter, each lease will extend automatically, on an individual basis, for up to four additional five-year periods unless we provide the lessor with six months’ advance notice that we do not intend that any individual option extension become effective. Each option to renew a lease in each of the four option periods shall include a rent increase equal to 5% of the rent payable for the applicable previous option period.
Protalix BioTherapeutics was established in 1993. It was founded by Yoseph Shaaltiel, who received his Ph.D. in Plant Biochemistry from the Weizmann Institute in Israel and served in the Biology Department of the Israel Defense Forces' Biological and Chemical Center. One of the earliest and largest investors in the company was Phillip Frost. Protalix has two Nobel Prize winners (Chemistry) in its Scientific Advisory Board, Roger Kornberg Ph.D and Prof. MD. Aaron Ciechanover.
In its early days Protalix operated out of a warehouse in the town of Qiryat Shemona in northern Israel. On July 19, 2005, Protalix Biotherapeutics announced the closing of a $5.3 million private placement of its series C preferred stock. Protalix entered into a partnership agreement with Teva Pharmaceutical Industries in 2006 for the development of two proteins and in 2009 signed a collaboration agreement with Pfizer for the development and commercialization of its taliglucerase alfa treatment. Also in 2009, Protalix reported that Frost & Sullivan presented the company with its 2009 European Orphan Diseases
Market Product Innovation of the Year Award. In 2011 Protalix announced that the U.S. Food and Drug Administration had approved the company's manufacturing facility in Karmiel.
Protalix initially became a public company through a reverse merger process with Orthodontix, a company which was at the time traded "over the counter" on the NASDAQ. This merger was completed on December 31, 2006, and is notable as one of the largest reverse mergers executed, valuing the joint entity at almost $1 billion. It subsequently applied for a listing on the AMEX, and sold 10 million shares in a public offering.
Protalix has been using cultured plant cells to manufacture biopharmaceuticals. As of 2017, Protalix has one FDA approved product sold by Pfizer in the U.S. and currently developing four products:
Taliglucerase alfa (Elelyso) – a recombinant glucocerebrosidase enzyme produced from transgenic carrot cell cultures. Known also as Elelyso, taliglucerase won approval from the U.S. Food and Drug Administration in May 2012 as an orphan drug for the treatment of Type 1 Gaucher's disease. Protalix has licensed global development and commercialization rights for Elelyso to Pfizer, except for Brazil, where Protalix retains full rights. Brazil has the third largest number of Gaucher patients identified worldwide, after the U.S. and Israel. The Brazilian National Health Surveillance Agency, known as ANVISA, granted regulatory approval for Elelyso (Uplyso) to treat adults with Gaucher disease in March 2013, and extended that approval to children in December 2016.
Alidornase alfa (PRX-110) – proprietary plant cell-expressed recombinant form of human deoxyribonuclease I (DNase I), that Protalix has designed, through chemical modification, to be resistant to inhibition by actin. DNase I is part of current Cystic Fibrosis therapy, intended to reduce sputum viscosity that accumulates in the lungs of Cystic Fibrosis patients, which exposes patients to recurrent infections and compromises lung function. AIR DNase (alidornase alfa), developed to make mucus in the lungs of cystic fibrosis patients less sticky, showed remarkably good results in 2017.
Pegunigalsidase alfa (PRX-102) – plant cell culture expressed and a chemically modified version of the recombinant alpha-Galactosidase-A protein. Protein sub-units are covalently bound via chemical cross-linking using PEG chains, resulting in a more active and stable molecule than the current available versions. Protalix is currently conducting Phase 3 clinical trial for PRX-102 for the treatment of Fabry Disease following a successful meeting with U.S. Food and Drug Administration. Protalix announced positive results from its clinical trial for PRX-102. Pegunigalsidase alfa is being developed to replace Fabrazyme and interim data shows potential superiority in efficacy.
Read the full text
OPRX-106 – plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain (TNFRII-Fc), in development for oral administration. If successful, OPRX-106 will be the first ever oral enzyme treatment as currently there are no other oral enzyme treatments available.
PRX-105 – a recombinant human Acetylcholinesterase, produced from genetically modified cell line of tobacco cells (Nicotiana tabacum), which can be used as a counter-measure against nerve agents attack. PRX-105 completed exploratory Phase I clinical trials.
Mar 17, 2025Reported quarterly or annual results67
Nov 14, 2024Reported quarterly or annual results68
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
184 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 60 major events, 56 insider forms, 11 large holders, 36 other. The latest 20:
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Protalix Biotherapeutics Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
From the cover page of the 10-K filed Mar 18, 2026 (Section 12(b) of the Exchange Act).17
Risk factors and legal proceedings
The risks Protalix Biotherapeutics Inc names in Item 1A of its 10-K filed Mar 18, 2026: 73 risks under these headings, as written.17
Risks Related to the Commercialization and Continued Approval of our Products
●We currently depend heavily on the generation of revenues from the sales of Elfabrio and Elelyso.
●Any current products or future product candidates may cause serious adverse events or undesirable side effects.
●There may be safety issues regarding our products that were not known at the time of approval are discovered.
●Physicians, patients, third party payors and others in the medical community might not accept and use our current or future products.
●Coverage and reimbursement may not be available for our current or future products in all territories.
Risks Related to Our Business
●We have a limited commercial operating history.
●We may fail to supply drug substance to Chiesi or Pfizer.
●We may be unable to enhance our portfolio of product candidates.
●We or our providers may experience manufacturing problems.
●Reliance on third parties for final processing of our products and product candidates exposes us to a number of risks.
The other 63 risks
●Developments by competitors may render our products or technologies obsolete or non-competitive.
●If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud.
●Our internal computer systems, or those used by our third-party contractors or consultants, may fail or suffer security breaches and expose our company to liabilities.
●We may face product liability claims.
●Our ability to utilize net operating loss carryforwards may be limited.
Risks Related to Clinical Trials and Regulatory Matters
●We may not obtain the necessary U.S., EMA, or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all.
●We may experience delays in obtaining regulatory approvals with respect to any drug candidate.
●Preclinical and clinical trials are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs.
●If the results of our clinical trials do not support our claims relating to a drug candidate, or if serious side effects are identified, the completion of development of such drug candidate may be significantly delayed or we may be forced to abandon development altogether.
●We may find it difficult to enroll patients in our clinical trials or patients may discontinue their participation in our clinical trials.
●Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
●Dependence upon third-party service providers in connection with our clinical trials expose us to risks.
Risks Related to our Financial Condition and Capital Requirements
●We may need to raise additional capital to operate our business, which may not be available on favorable terms, or at all.
Risks Related to Intellectual Property Matters
●We may fail to adequately protect or enforce our intellectual property rights or secure rights to third party patents, and the terms of certain of our patents are limited or have expired.
Risks Relating to our Operations in Israel
●Our results may be adversely affected by military, political and economic conditions in Israel.
●The Israeli government grants we have received for certain research and development expenditures restrict our ability to manufacture products and transfer technologies outside of Israel and require us to satisfy specified conditions.
Risks Related to Investing in our Common Stock
●The market price of our common stock may fluctuate significantly; future sales of our common stock could reduce our stock price.
●Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses or divert management’s attention.
●Delaware law and our organizational documents contain certain anti-takeover provisions.
●Our Amended and Restated Bylaws provide for limits on our stockholders’ ability to obtain a favorable judicial forum.
We currently depend heavily on the generation of revenues from the sales of Elfabrio and Elelyso. Any failure to successfully commercialize Elfabrio will have a material adverse effect on our business, results of operations, and financial condition.
Any current products or future product candidates may cause serious adverse events, or SAEs, undesirable side effects or have other properties that could halt their clinical development, prevent, delay, or cause the withdrawal of their regulatory approval, limit their commercial potential, or result in material negative consequences.
If safety issues regarding our products that were not known at the time of approval are discovered, or if we or the applicable marketing authorization holder fails to comply with continuing U.S. and applicable foreign regulations, commercialization efforts for our products could be adversely affected and the products could lose their approval or their sales could be suspended.
If physicians, patients, third party payors and others in the medical community do not accept and use Elfabrio, Elelyso or any other future products, our ability to generate revenue from product sales will be materially impaired.
If the market opportunities for Elfabrio, Elelyso or any other future products are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.
Coverage and reimbursement may not be available for Elfabrio, Elelyso, or any other future products in all territories, which could diminish sales of our products or adversely affect the profitably of such sales.
We and our collaborating partners may be subject, directly or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. If we or our collaborating partners are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
We have a limited commercial operating history which may limit the ability of investors to make an informed investment decision.
Any failure by us to supply drug substance to Chiesi or Pfizer may have a material adverse effect on our business, results of operations, and financial condition.
Our strategy, in certain cases, is to enter into collaboration agreements with third parties to develop product candidates. Failure to enter into such agreements, or non-compliance by us or our collaborators with such agreements, may have a material adverse effect on our business, results of operations, and financial condition.
Fiocruz is not complying, and we expect they will continue to not comply, with the terms and conditions of the Brazil Agreement.
We have limited experience in selling, marketing or distributing products and limited internal capability to do so.
If we are unable to enhance our portfolio of product candidates, our business may be adversely affected.
The manufacture of our products is an exacting and complex process, and any manufacturing problems encountered by us or certain of our providers may have a material adverse effect on our business, results of operations, and financial condition.
We rely on third parties for final processing of Elfabrio, Elelyso, and our other product candidates, which exposes us to a number of risks that may delay development, regulatory approval, and commercialization of Elfabrio, Elelyso, or our other product candidates or result in higher product costs.
Developments by competitors may render our products or technologies obsolete or non-competitive which would have a material adverse effect on our business, results of operations, and financial condition.
If we in-license drug candidates, we may delay or otherwise adversely affect the development of our existing drug candidates, which may negatively impact our business, results of operations and financial condition.
If we acquire companies, products, or technologies, we may face integration risks and costs associated with those acquisitions that could potentially negatively impact our business, results of operations and financial condition.
We depend upon key employees and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop and market our products.
Under current U.S. and Israeli laws, we may not be able to enforce employees’ covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees.
If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.
Our internal computer systems, or those used by our third-party contractors or consultants, may fail or suffer security breaches, resulting in liability and harm to our reputation, which could negatively affect our business, results of operation and financial condition. We may face liability if we breach our obligations related to the protection, security, nondisclosure of confidential information or disclosure of sensitive data or fail or are perceived to fail to comply with applicable data protection laws and regulations, or consumer protection laws, regulations and standards.
We could be subject to securities class action litigation.
In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology companies have experienced significant stock price volatility in recent years. Any such litigation, could result in substantial costs and divert management’s attention and resources, which could have a material adverse effect on our business, results of operations, and financial condition.
If product liability claims are brought against us, it may result in reduced demand for our products and product candidates or damages that exceed our insurance coverage.
Our ability to utilize net operating loss carryforwards may be limited.
Our corporate structure may create U.S. federal income tax inefficiencies.
We are a holding company with no operations of our own.
Outbreaks of contagious disease or similar public health threats could materially and adversely affect our business, results of operations and financial condition.
Our operating costs and business operations could be adversely affected by climate-related events and increasing regulatory requirements and security.
and goals related to climate action could adversely affect our reputation with suppliers and customers, financial performance, or the ability to recruit and retain talent.
We may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all, which would have a material adverse effect on our business, results of operations, and financial condition.
We are subject to extensive governmental regulation including the requirements of the FDA and other comparable regulatory authorities before our drug candidates may be marketed.
Delays in obtaining regulatory approvals with respect to any drug candidate may materially and adversely affect our prospects, business, results of operations and financial condition.
Preclinical and clinical trials are very expensive, time-consuming, and difficult to design and implement and may result in unforeseen costs, which may have a material adverse effect on our business, results of operations, and financial condition.
If the results of our clinical trials do not support our claims relating to a drug candidate, or if serious side effects are identified, the completion of development of such drug candidate may be significantly delayed or we may be forced to abandon development altogether, which will significantly impair our ability to generate product revenues.
Interim, top-line or preliminary data from clinical trials that we announce or publish may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.
We may find it difficult to enroll patients in our clinical trials, or patients may discontinue their participation in our clinical trials, which could cause significant delays in the completion of such trials or may negatively impact the results of these studies and extend the timeline for completion of our development programs or cause us to abandon one or more clinical trials.
Our clinical trials depend upon third-party service providers and, accordingly, the results of our clinical trials and such research activities are subject to delays and other risks which are, to a certain extent, beyond our control, which could impair our clinical development programs and our competitive position.
We have limited experience in regulatory affairs compared to our larger competitors, and some of our drug candidates may be based on new technologies. These factors may affect our ability or the time we require to obtain necessary regulatory approvals.
Uncertainty surrounding and future changes to healthcare law in the United States and other United States Government related mandates may adversely affect our business.
In the coming years, additional changes could be made to U.S. governmental healthcare programs and U.S. healthcare laws that could significantly impact the success of our products. We cannot predict what other legislation relating to our
business or to the health care industry may be enacted, or what effect such legislation or other regulatory actions may have on our business, prospects, operating results, and financial condition.
Legal proceedings
We are not involved in any material legal proceedings.
